Infliximab 100mg/mL
| Product Overview |
| Generic Name | Infliximab 100mg/mL |
| Form | IV Injection Vial |
| Strength | 100mg |
| Manufacturing & Regulatory |
| Country | India/USA/EU |
| GMP Compliance | WHO/cGMP-compliant |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Available from supplier on request |
| Logistics & Export |
| MOQ | 10 units |
| Shelf Life | 24 months |
| Storage | 2–8 °C, protect from light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Use and Indications for Infliximab: Infliximab is a chimeric monoclonal antibody indicated for the treatment of autoimmune inflammatory disorders, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It targets and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammation and immune-mediated tissue damage.
Request for Quote
